Targets › ITGA11
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2026.
Integrin alpha-11/beta-1 is a receptor for collagen. (UniProt, Q9UKX5)
Open in Phaseline: the race on ITGA11, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Peter MacCallum Cancer Centre, Australia | Radium-223 Bone-targeting alpha-emitting radiopharmaceutical targeting bone metastases | ITGA11 | Phase 1 | Metastatic Castration-resistant Prostate Cancer | Dec 2026 |
Metastatic Castration-resistant Prostate Cancer (1)
small molecule (1)
Peter MacCallum Cancer Centre, Australia (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.